Breast Cancer Research and Treatment

Article	Citations
Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic	158
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer	85
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, T	73
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies	65
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer	64
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer	60
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment	58
Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018	58
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival	57
International variation in breast cancer incidence and mortality in young women	57
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer	52
Body composition and breast cancer risk and treatment: mechanisms and impact	48
A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns	45
Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study	44
Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors	44
High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis	44
Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City	40
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer	39
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early	37
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial	36
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)	36
Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis	36
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer	34
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial	33
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy a	31

Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score	31
Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women	31
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors	30
The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype	30
Immune microenvironment in different molecular subtypes of ductal breast carcinoma	29
Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis	29
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies	29
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study	29
Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial	28
Meta-analysis of prepectoral implant-based breast reconstruction: guide to patient selection and current outcomes	28
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)	28
Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study	28
TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway	27
Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis	27
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database	27
The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer	26
Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy	26
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes	25
Spatial location of local recurrences after mastectomy: a systematic review	25
The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer	25
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol	25
Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT	25
Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study	25
Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients	25
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis	25
Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors	24
Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer	24
Association between thyroid gland diseases and breast cancer: a case–control study	24
A comparison of two non-radioactive alternatives to wire for the localization of non-palpable breast cancers	24
Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors	24
Immunotherapy toxicity: identification and management	24
PIK3CA-mutations in breast cancer	24
Psychoneurological symptom cluster in breast cancer: the role of inflammation and diet	24
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer	24
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers	23
Hormone replacement therapy and mammographic density: a systematic literature review	23
Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography	23
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population	23
Characterization of estrogen receptor-low-positive breast cancer	23
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, place	23
Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no speci	23
A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation	23
Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells	23
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer	23
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific sub	22
Sexual health after a breast cancer diagnosis in young women: clinical implications for patients and providers	22
The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review	22
Clinical trials of immunotherapy in triple-negative breast cancer	22
Outcomes following lymphaticovenous anastomosis (LVA) for 100 cases of lymphedema: results over 24-months follow-up	22
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer	22

ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells	22
Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study	21
Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile	21
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical	21
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients	21
Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients	21
Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study	21
Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer	20
Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells	20
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway	20
Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival	20
A systematic review of multimodal prehabilitation in breast cancer	20
Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer	20
Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model	20
Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer	20
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer	20
Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study	20
HER2-targeted therapy influences CTC status in metastatic breast cancer	20
NSDHL promotes triple-negative breast cancer metastasis through the TGFβ signaling pathway and cholesterol biosynthesis	20
Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer	19
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors	19
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer	19
Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer	19
The WISDOM study: a new approach to screening can and should be tested	19
Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis	19
The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis	19
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic	19
Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?	19
Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study	19
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer	19
Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study	19
Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up	18
Sensory profiles in women with neuropathic pain after breast cancer surgery	18
Width of margins in phyllodes tumors of the breast: the controversy drags on?—a systematic review and meta-analysis	18
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer	18
Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system	18
Allostatic score and its associations with demographics, healthy behaviors, tumor characteristics, and mitochondrial DNA among breast cancer patients	18
Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors	18
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)	18
Management of early breast cancer during the COVID-19 pandemic in Brazil	18
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies	18
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function	18
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)	18
COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic	18
Predictive risk factors of complications in different breast reconstruction methods	18
Ultrasound visibility of select breast biopsy markers for targeted axillary node localization following neoadjuvant treatment: simulation using animal tissue models	17
Association between selenium intake and breast cancer risk: results from the Women’s Health Initiative	17
FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact	17
SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study	17
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer	17
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer	17
Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis	17
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research	17
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer	17
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review	17
Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer	17
Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells	17
Prospective surveillance model in the home for breast cancer-related lymphoedema: a feasibility study	17
Breast cancer resistance mechanisms: challenges to immunotherapy	17
Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial	17
Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer	17
False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant system	17
LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis	17
Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation	17
Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach	17
Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey	17
A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity	17
Implications of missing data on reported breast cancer mortality	17
Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management	16
FASN inhibition as a potential treatment for endocrine-resistant breast cancer	16
Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study	16
Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer	16
CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA	16
Tumor subtypes and survival in male breast cancer	16
Covid-19 related oncologist’s concerns about breast cancer treatment delays and physician well-being (the CROWN study)	16
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer	16
Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years	16
A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer	16
Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy	16
Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis	16

Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer	16
Presentation and characteristics of breast cancer in young women under age 40	16
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations	16
Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017	16
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase	16
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?	15
Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients	15
Clinical trial data and emerging strategies: HER2-positive breast cancer	15
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment	15
The epithelial sodium channel has a role in breast cancer cell proliferation	15
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer	15
Racial/ethnic differences in supplemental imaging for breast cancer screening in women with dense breasts	15
Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution	15
Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population	15
Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis	15
The shape of breast cancer	15
Standardization of the tumor-stroma ratio scoring method for breast cancer research	14
Breast cancer vaccines for treatment and prevention	14
Patient preferences for locoregional therapy in early-stage breast cancer	14
Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction	14
Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen	14
The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer	14
COVID-19 vaccination and breast cancer surgery timing	14
Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial	14
Stage-specific survival has improved for young breast cancer patients since 2000: but not equally	14
Advances in the prevention and treatment of breast cancer-related lymphedema	14
Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials	14
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metasta	14
miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis	14
Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer	14
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients	14
Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade	13
Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer	13
Radial scars and complex sclerosing lesions on core needle biopsy of the breast: upgrade rates and long-term outcomes	13
Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery	13
HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells	13
Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing	13
FOXA1 is a determinant of drug resistance in breast cancer cells	13
Increasing accrual of minority patients in breast cancer clinical trials	13
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer	13
Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomes	13
Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer	13
The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements	13
Outcomes of systemic therapy in metastatic phyllodes tumor of the breast	13
Pre-operative axillary ultrasound with fine-needle aspiration cytology performance and predictive factors of false negatives in axillary lymph node involvement in early breast cancer	13
Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer	13
Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients	13
High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer	13
Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanc	13
Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer	13
Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?	13
Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population	13
UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin	13
A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients	12
The influence of mastectomy and reconstruction on residual upper limb function in breast cancer survivors	12
(Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic	12
Healthcare providers’ adherence to breast cancer guidelines in Europe: a systematic literature review	12
Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments	12
Somatic mutations of triple-negative breast cancer: a comparison between Black and White women	12
Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method	12
Association of mammographic density measures and breast cancer “intrinsic” molecular subtypes	12
An overview of genetic services delivery for hereditary breast cancer	12
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer	12
Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy	12
Does oncoplastic surgery increase immediate (30-day) postoperative complications? An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database	12
Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study	12
Low RAI2 expression is a marker of poor prognosis in breast cancer	12
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer	12
Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study	12
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer	12
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles	12
Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer	12
Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer	12
Exercise training affects hemodynamics not cardiac function during anthracycline-based chemotherapy	12
Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors	12
Nomograms for prediction of overall and cancer-specific survival in young breast cancer	12
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial	12
Escalating de-escalation in breast cancer treatment	12
Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer	12
Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression	12
Risk factors for breast cancer subtypes among Black women undergoing screening mammography	12
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer	12
M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma	12
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review	12
Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy	12
Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers	11
Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase	11
Factors associated with late risks of breast cancer-specific mortality in the SEER registry	11
The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer	11
The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery	11
Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants	11
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer	11
Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer	11
Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire	11
Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women	11